TeneoBio and Tesaro develop next-gen immuno-oncology therapies
Executive Summary
TeneoBio Inc. will use its transgenic antibody production platforms to discover new therapeutic multi-specific antibodies for up to six oncology targets for Tesaro Inc. Tesaro gets exclusive global rights to compounds resulting from the deal.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
- Transgenics
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice